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Effect of glucocorticoid administration on improving the outcomes of kidney and liver allografts has not been clearly elucidated.
This study investigated the effect of prednisolone administration after onset of brain death (BD) on kidney and liver in a controlled
rat model of BD. BD was induced in rats by inflating an epidurally placed balloon catheter. Animals were treated with saline
or prednisolone (5, 12.5, or 22.5mg/kg) one hour after the onset of BD. After 4 hours of BD, experiments were terminated and
serum and tissues were collected. Tissue gene and protein expression were measured for markers of inflammation, apoptosis, and
cellular stress response markers. Prednisolone caused a reduction of plasma levels of IL-6, while the tissue expression of IL-6, IL-
1𝛽, andMCP-1 in both kidney and liver were also reduced. Creatinine plasma levels, complement (C3) expression, HSP-70, HO-1,
Bcl2/BAX ratio, and PMN influx did not significantly change in kidney nor liver. Plasma AST and LDH levels were increased in the
prednisolone treated group. Our results demonstrate prednisolone can has an anti-inflammatory effect mediated through reducing
serum circulating cytokines. However, this anti-inflammatory effect does not translate into improved kidney function and indeed
was associated with increased liver injury markers.
1. Introduction
The shortage of organs for transplantation is one of the most
important problems facing the transplant community today.
Identifying how injury occurs in donor organs and how this
injury can be ameliorated will result in increased numbers of
suitable organs for transplantation.
To address this, a number of different approaches have
been described for the management and optimisation of
BD organ donors. There is general consensus about the
importance of maintaining hemodynamic stability. As a con-
sequence donor care bundle pathways have been developed
and include targets for mean arterial pressures and cardiac
output amongst other physiological parameters [1].
The role of hormonal or anti-inflammatory treatments
remains controversial however despite some promising
experimental evidence [2, 3]. Many donor management
protocols usually include steroids, but this indication is based
on poor quality evidence and is subject to considerable
debate in the literature [4–9]. The distinguishing effects of
glucocorticoid administration on the kidney and liver have
not been fully elucidated.
Brain death causes a complex disturbance of normal
homeostatic systems resulting in hemodynamic instability
[10–13], hormonal impairment [14–16], and inflammation
[17]. Brain death is the result of significant cerebral ischemia
and intracranial hypertension resulting in parasympathetic
activity followed by severe vasoconstriction due to an over-
riding sympathetic response by endogenous catecholamines.
This catecholamine activity is also called the autonomic or
catecholamine storm and is part of the Cushing reflex, a phys-
iological response to maintain cerebral perfusion. Because of
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the progressive paralysis of the spinal cord and the loss of
vasomotor tone, hemodynamic instability characterizes this
period [18–20].
In addition to hemodynamic instability, hormonal secre-
tion is altered. Pituitary function is affected as ACTH
secretion is initially increased, resulting in a transient rise
in cortisol levels during brain death; this then diminishes
however, progressing to below baseline levels [3]. A reduction
in thyroid stimulating hormone (TSH) also occurs.
During brain death, a systemic inflammatory state is
characterized by circulating cytokines, including interleukin-
6 (IL-6), interleukin-10 (IL-10), Tumor Necrosis Factor-alpha
(TNF-𝛼), Transforming Growth Factor-beta (TGF-𝛽), and
also monocyte chemotactic protein 1 (MCP-1); it is widely
reported [21–23]. This inflammatory environment permits
an influx of inflammatory cells into organs including the
kidneys, liver, and lung, leading to a local inflammatory
response culminating in cellular apoptosis [24, 25].Theorigin
of this inflammatory status is not well understood but may
include the release of cerebral inflammatory cytokines which
cross a disrupted blood brain barrier, complement activation
[26, 27], and increased intestinal permeability [28].
In brain death glucocorticoid administration could have
several beneficial effects including anti-inflammatory prop-
erties and the ability to augment chromaffin cells production
of endogenous adrenaline [29].The anti-inflammatory effects
of steroids result from the pleiotropic interaction with the
glucocorticoid receptor. The cortisol-glucocorticoid receptor
complex can act through genomic and nongenomic down-
stream signalling pathways within the cell. This involves
the dissociation of heat shock proteins and the interaction
with membrane-associated receptors and second messengers
and activation of transcription factors such as nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-𝜅B) [30].
We investigated whether the quality of liver and kidney
grafts could be improved by prednisolone treatment after
brain death induction in a rodent model.
We hypothesised that prednisolone treatment adminis-
tered after brain death induction could reduce the inflamma-
tory response in brain-dead rats and improve kidney function
but not liver cellular injury based on our previous work [31].
2. Methods
2.1. Animal Brain Death Model. All animals received care
in compliance with the guidelines of the Institutional Ani-
mal Care and Use Committee-Rijksuniversiteit Groningen
(IACUC-RUG) according to Experiments on Animals Act
(1996) issued by the Ministry of Public Health, Welfare and
Sports of Netherlands.The IACUC-RUG approved this study
and all animal care actions. Male adult Fisher F344 rats (250–
300 g) were used. Brain death (BD) was induced as described
previously [32]. In brief, the procedurewas as follows: animals
were anesthetized using isoflurane with O
2
. Cannula was
inserted in the femoral artery and vein for continuous mean
arterial pressure monitoring and administration of fluids.
Animals were intubated via a tracheostomy and ventilated
throughout the experiment. Through a frontolateral hole in
the skull, a number 4 Fogarty catheter (Edwards Lifesciences
Co, Irvine, CA) was placed epidurally and slowly inflated
(16 𝜇L/min) with saline using a syringe pump (Terufu-
sion, Termo Co, Tokyo, Japan). During balloon inflation, a
hypotensive period of about 15 minutes occurred followed
by a sudden increase in blood pressure. When the blood
pressure returned to its basal level (80mmHg) during the
increasing peak, inflation of the balloon was stopped and
anesthesiawaswithdrawn.Theballoonwas kept inflated until
the end of the experiment. Brain death was confirmed 30min
after anesthesia was terminated by the absence of corneal
and pupillary reflexes. Mean arterial blood pressure was
maintained above 80mmHg throughout the BD period using
HAES 10% (Fresenius Kabi AG, Bad Homburg, Germany) in
bolus of 0.5mL with a maximum infusion rate of 1mL/hr.
If HAES had insufficient effect on blood pressure, nora-
drenaline (NA) 0.01mg/mL infusion was administered. A
homeothermic blanket control system was used throughout
the BD maintenance period. Four hours after determination
of BD, a laparotomy was performed and blood was collected
from the aorta. Organs were subsequently flushed with 0.9%
cold saline and snap frozen in liquid nitrogen. Blood was
centrifuged for 10min at 960 g and plasma collected and
stored at −80∘C.
Rats were randomly divided, each group consisting of six
to eight animals. Prednisolone or saline was administered
intravenously, one hour after BD induction. Prednisolone
dosage was chosen based on previous experiments.
The following experimental groups can be distinguished:
(i) Brain-dead animals receiving saline (𝑛 = 7).
(ii) Brain-dead animals receiving 22.5mg/Kg prednisol-
one (𝑛 = 7).
(iii) Brain-dead animals receiving 12.5mg/Kg prednisol-
one (𝑛 = 8).
(iv) Brain-dead animals receiving 5mg/Kg prednisolone
(𝑛 = 6).
2.2. Plasma Determinations. At the Laboratory Center of
the University Medical Center Groningen (Mega, Merck),
the following measurements were determined in a routine
fashion: creatinine in plasma by the Jaffe method [33] and
alanine aminotransferase and aspartate aminotransferase
enzyme activity in plasma [34].
The level of IL-6 in the plasma was determined by a
rat enzyme-linked immunosorbent assay (IL-6 ELISA) kit
(R&D Systems Europe Ltd. Abingdon, OxonOX14 3NB, UK),
according to the manufacturer’s instructions. All samples
were analyzed in duplicate and read at 450 nm.
2.3. RNA Isolation and cDNA Synthesis. Total RNA was
isolated from whole kidneys and liver sections by using
TRIzol (Life Technologies, Gaithersburg, MD). RNA samples
were verified for absence of genomic DNA contamination
by performing RT-PCR reactions in which the addition of
reverse transcriptase was omitted, using glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) primers. For cDNA
synthesis, 1 𝜇L T11VN Oligo-dT (0.5 𝜇g/𝜇L) and 1 𝜇g mRNA
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Table 1: Primer sequences used for Real-Time PCR.




























were incubated for 10min at 70∘C and cooled directly after
that. cDNA was synthesized by adding a mixture containing
0.5 𝜇L RnaseOUT ribonuclease inhibitor (Invitrogen, Carls-
bad,USA), 0.5 𝜇LRNasewater (Promega), 4 𝜇L 5x first strand
buffer (Invitrogen), 2𝜇L DTT (Invitrogen), 1 𝜇L dNTPOs,
and 1 𝜇L M-MLV reverse transcriptase (Invitrogen, 200U).
The mixture was held at 37∘C for 50min. Next, reverse
transcriptase was inactivated by incubating the mixture for
15min at 70∘C. Samples were stored at −20∘C.
2.4. Real-Time PCR. Fragments of several genes were ampli-
fied with the primer sets outlined in Table 1. Pooled cDNA
obtained from brain-dead rats was used as internal refer-
ences. Gene expression was normalized with the mean of
𝛽-actin mRNA content. Real-Time PCR was carried out in
reaction volumes of 15𝜇L containing 10 𝜇L of SYBR Green
mastermix (Applied biosystems, Foster City, USA), 0.4𝜇L of
each primer (50 𝜇M), 4.2 𝜇L of nuclease free water, and 10 ng
of cDNA. All samples were analyzed in triplicate. Thermal
cycling was performed on the TaqMan Applied Biosystems
7900HT Real-Time PCR System with a hot start for 2min at
50∘C followed by 10min 95∘C. Second stage was started with
15 s at 95∘C (denaturation step) and 60 s at 60∘C (annealing
step and DNA synthesis). The latter stage was repeated 40
times. Stage 3 was included to detect formation of primer
dimers (melting curve) and begins with 15 s at 95∘C followed
by 60 s at 60∘C and 15 s at 95∘C. Primers were designed with
Primer Express software (Applied Biosystems) and primer
efficiencies were tested by a standard curve for the primer
pair resulting from the amplification of serially diluted cDNA
samples (10 ng, 5 ng, 2.5 ng, 1.25 ng, and 0.625 ng) obtained
from brain-dead rats. PCR efficiency was found to be 1.8
< 𝜖 < 2.0. Real-Time PCR products were checked for product
specificity on a 1.5% agarose gel. Results were expressed as
2−ΔΔCT (CT: Threshold Cycle).
2.5. Immunohistochemistry. To detect polymorphonuclear
cells (PMN) in kidney and liver, immunohistochemistry was
performed on 5 𝜇m tissue cryosections. Sections were fixated
for 10min using acetone. Next, sections were stained with
HIS-48 mAb (supernatant, two times diluted) using an indi-
rect immunoperoxidase technique. Endogenous peroxidase




0.01% in phosphate-buffered saline
for 30min. After thorough washing, sections were incubated
with horseradish peroxidase-conjugated rabbit anti-mouse
IgG as a secondary antibody for 30min, followed by goat anti-
rabbit IgG as a tertiary antibody for 30min (both fromDako,
Glostrup, Denmark). The reaction was developed using 9-





Sections were counterstained usingMayer hematoxylin solu-
tion (Merck, Darmstadt, Germany). Negative antibody con-
trols were performed. Localization of immunohistochemical
staining was assessed by light microscopy. For each tissue
sample, positive cells were counted in 10 microscopic ran-
dom fields of the tissue at 40x magnification. Results were
presented as number of positive cells per glomerulus in the
kidney and number of positive cells per area (𝜇m2) in the
liver.
2.6. Statistical Analysis. For statistical analysis between the
four experimental groups, the Kruskal-Wallis test was per-
formed, followed byDunn’s posttests for comparison between
groups, with 𝑝 < 0.05 regarded as significant. Results are
presented as mean ± SD (standard deviation). Statistical
analyses were performed using Prism 5.0. GraphPad.
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Table 2: HAES and noradrenaline requirements.
Group Total HAES 10%infusion (mL)
Total noradrenaline
infusion (mL)
Saline 2.8 ± 1.9 2.3 ± 2.2
22.5mg/Kg prednisolone 1.6 ± 1.3 0.3 ± 0.8
12.5mg/Kg prednisolone 1.5 ± 0.8 0.2 ± 0.5
5mg/Kg prednisolone 1.7 ± 1.1 0.3 ± 0.4























Figure 1: Blood pressure profile. The record started with the brain
death induction; we considered time 0 as the end of brain death
induction and the starting of brain death period.
3. Results
Induction of brain death showed a consistent and uniform
pattern in blood pressure with a mean induction time of 32,5
± 2,5 minutes which is similar to our previous publications
[31]. After brain death induction all animals were kept
with a mean arterial pressure of above 80mmHg during
the remainder of the experiment (Figure 1). No significant
difference was found in the requirement of HAES 10% (𝑝 =
0.44). The volume of noradrenaline required to keep blood
pressure above 80mmHg was significantly higher in the
saline group (𝑝 = 0.04, Table 2).
No significant difference was found in creatinine levels
between BD saline condition and prednisolone groups. An
increase of aspartate aminotransferase (AST) and lactate
dehydrogenase (LDH) plasma levels was associated with the
groups treated with the higher prednisolone dose compared
with saline treated group (AST: saline, 143.1 ± 68.59U/L and
22.5mg/Kg prednisolone group, 298.7 ± 123.1; LDH: saline,
331.7 ± 324.0U/L and 22.5mg/Kg prednisolone group, 1474
± 944.1 U/L). A decrease of IL-6 plasma levels was found in
all prednisolone groups compared with saline treated group
(IL-6: saline, 192± 146.3 pg/mL; 5mg/Kg prednisolone group,
21.33 ± 7.68 pg/mL; 12.5mg/Kg prednisolone group, 33.63 ±
36.68 pg/mL; and 22.5mg/Kg prednisolone group, 10.57 ±
9.79 pg/mL) (Figure 2).
In order to assess the anti-inflammatory effects of the
prednisolone treatment PMN influx was studied as well as
the expression of inflammatory genes in livers and kidney. No
significant difference was found in PMN influx to the kidney
nor liver due to prednisolone treatment (Figure 3). A decrease
in TNF-𝛼, IL-6, IL-1𝛽, and MCP-1 expression was found in
kidneys of rodents treated with prednisolone compared with
the control group. In the liver IL-6, IL-1𝛽, and MCP-1 were
downregulated in the prednisolone groups but the expression
of TNF-𝛼 was not modified by this treatment (Figure 4).
To assess complement activation, which has previously
been shown to be associated with brain death induced
organ injury, we studied the expression of the complement
component 3 (C3) in kidney and liver [35]. The relative C3
expression did not change due to prednisolone treatment in
both organs (Figure 5).
We studied the apoptotic pathway by B-cell lymphoma
2 (Bcl-2)/Bcl-2 associated X protein (BAX) ratio. No change
was found in the 22.5mg/Kg nor 12.5mg/Kg prednisolone
treated groups when compared with the saline treated group,
while a decrease in the Bcl-2/BAX ratio was found using the
lower dose of prednisolone in liver and kidney (Bcl-2/BAX
kidney: saline, 0.99 ± 0.30 and 5mg/Kg prednisolone group;
Bcl-2/BAX liver: saline, 0.09± 0.03 and 5mg/Kg prednisolone
group, 0.04 ± 0.01) (Figure 5).
We studied the effect of the interventions on the relative
expression of two cytoprotective genes, heme oxygenase 1
(HO-1) and HSP-70. Both the expressions of HO-1 and HSP-
70 were not modified in liver or kidney by the prednisolone
treatment (Figure 5).
4. Discussion
Disparity exists in the literature with regard to the beneficial
effects of steroids administration to the donor on the out-
comes of solid organ transplantation. Two recent systematic
reviews of Dupuis et al. and Rech et al. [4, 36] concluded
that evidence supporting the routine use of steroids in the
management of organ donors is conflicting. The lack of
knowledge about the effect of steroids on specific organs
such as the kidney and liver with regard to donation was the
stimulus to design and perform this study. We hypothesized
that prednisolone administration would reduce the donor
inflammatory response and improve the quality of both
kidney and liver allografts. Our initial observation concerned
improvements in the hemodynamic status of the brain-dead
rodents treated with prednisolone.
We have demonstrated that prednisolone improves the
hemodynamic status significantly reducing the noradrenaline
requirements. Dhar et al. [37] reported similar findings,
demonstrating a reduction in vasopressors utilized prior to
organ recovery when methylprednisolone or hydrocortisone
was administered to the donor. However a randomized
clinical trial by Venkateswaran et al. [38] concluded, as a sec-
ondary outcome, that methylprednisolone did not improve
cardiovascular function. A previous work by Venkateswaran
et al. [9] evaluated the effects of 1 g of methylprednisolone
administration to brain-dead organ donors 7 hours prior to
lung explantation, demonstrating no effect on increasing lung
yields but a reduction in lung water accumulation.
Despite this complex and contradictory background there
are physiological reasons to think that steroids can improve






















































































Saline 5mg/kg 12.5mg/kg 22.5mg/kg
Saline 5mg/kg 12.5mg/kg 22.5mg/kg
∗p < 0.05
Prednisolone
Figure 2: Plasma levels of kidney function marker (creatinine), liver injury markers (AST, LDH, and ALT), and interleukin-6 (IL-6).
hemodynamics. Corticoids as prednisolone have a mineralo-
corticoid effect which increase the sodium reuptake in the
kidney [39]. Moreover corticoids could increase the endoge-
nous production of adrenaline. These effects increase blood
pressure and it could be one reason of the hemodynamic
improvement in our model [40].
Another reason for a better hemodynamic performance
could be the beneficial effect of prednisolone in microcir-
culation. Sack et al. [41] show in an animal model that
prednisolone prevents injury of the bowel induced by extra-
corporeal circulation using in vivo microscopy based on
labeled dextran. The influence of brain death over micro-
circulation has been studied by Simas et al. [42] proving
that mesenteric microcirculation is decreased during brain
deathmeasuredwith in vivomicroscopy. Yamagami et al. [43]
using a similar methodological approach proved that hepatic
microcirculation is affected by brain death. However more
research needs to be performed to understand the impact
of microcirculation impairment during brain death and its
potential treatment.
To delineate the anti-inflammatory effect of prednisolone
we tested three different doses of this drug after brain
death induction in our animal model. We found a strong
anti-inflammatory response due to prednisolone treatment,
measured by IL-6 plasma levels and the expression of IL-6,
IL-1𝛽, andMCP-1 in liver and kidney tissue. These results are
in line with a randomized clinical trial by Kotsch et al. [6]
demonstrating a significant downregulation of proinflamma-
tory cytokines whichwas associatedwith a reduced incidence
of acute rejection in the liver transplantation setting. In
contrast, Amarschek et al. [44] conclude that steroid donor
treatment did not improve outcomes after liver transplan-
tation, but no inflammatory markers were measured in this
study. Others in the realms of kidney transplantation have
failed to detect a significant improvement in the incidence or
duration of posttransplantation acute renal failure in allograft
recipients when 1 g of methylprednisolone is administered to
donors 3 hours prior to explantation, despite the suppression
of inflammatory response in transplanted kidneys [45].
In a previous study we showed that prednisolone admin-
istered before the induction of brain death in fact reduced
inflammation measured by IL-6 plasma levels and renal
and liver expression of proinflammatory cytokines like IL-
6, IL-1𝛽, MCP-1, and TNF-𝛼. Interestingly prednisolone
pretreatment did improve renal function measured by crea-
tinine plasma levels but did not improve liver cellular injury
measured by AST, ALT, and LDHplasma levels [31].We think
that this differing effect may be related with the persistence
6 BioMed Research International
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Figure 3: PMN infiltration quantification and staining. (a) Liver tissue from a BD animal treated with saline. (b) Liver tissue from a BD
animal treated with 22.5mg/Kg of prednisolone. (c) Liver tissue from a BD animal treated with 12.5mg/Kg of prednisolone. (d) Liver tissue
from a BD animal treated with 5mg/Kg of prednisolone. (e) Kidney tissue from a BD animal treated with saline. (f) Kidney tissue from a BD
animal treated with 22.5mg/Kg of prednisolone. (g) Kidney tissue from a BD animal treated with 12.5mg/Kg of prednisolone. (h) Kidney
tissue from a BD animal treated with 5mg/Kg of prednisolone. (i) Quantification of liver samples. (j) Quantification of kidney samples.
of complement activation (C3) in the liver and downregu-
lation of protective cellular mechanisms such as heat shock
proteins.
Thus, contrary to our hypothesis and our other study,
post-brain death induction therapywith prednisolone did not
improve organ quality in terms of renal function, asmeasured
by creatinine levels. Additionally and in contrast to our
previous results, we found a persistent complement activation
in the kidney of BD rats treated with prednisolone treatment.
One of the differences which may account for this, in part,
is the different durations between time of administration and
time of retrieval of organs. In the current study prednisolone
was administered after an hour of BD andBDwasmaintained
for 3 hours. This time window may have been too short to
observe the benefits seen in the previous study.
In addition, the relative expression of genes related with
cellular protection (HSP-70 and HO-1) was not modified by
prednisolone treatment. In addition, PMN influx was not
reduced in the liver nor kidney by prednisolone treatment.
This may reflect the ongoing cellular injury in both organs
and the short follow-up period after prednisolone adminis-
tration.
In previous studies we have shown that following the
onset of BD apoptosis is increased in both the liver and
kidney [27, 31]. However, apoptosis seems to be triggered
independently of the systemic inflammatory response, per-
haps by other factors such as cellular stress, hypoxia, and
alteredmetabolism.The complement system can be activated
by apoptotic cells. Indeed, the pattern recognition molecule
(PRM) C1q activates complement by recognizing distinct
structures directly on microbial and apoptotic cells. The
complement system creates cellular injury by promoting
phagocytosis and anaphylaxis reaction [46]. Therefore, we
hypothesize that the persistent C3 complement expression
may account for the lack of responsiveness of the kidney
and liver to the anti-inflammatory effects of prednisolone.
Further experiments need to be performed to test this
hypothesis.
However, work performed by Damman et al. [47] sup-
ports this idea, as they have demonstrated that BD induced
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Figure 4: Relative expression of inflammatory genes. (a) Kidney and (b) liver.
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Figure 5: Relative expression of C3 complement, heme oxygenase-1 (HO-1), and heat shock protein 70 (HSP-70). Ratio of the relative
expression of Bcl-2/BAX. (a) Kidney and (b) liver.
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complement activation and cell injury can be targeted and
improves the outcomes of transplantation. Considering these
results, maybe the combination of steroids and anticom-
plement activation therapy could be a better approach to
improve organ quality in BD donors.
5. Conclusion
Our study has demonstrated that prednisolone adminis-
tration following brain death improves the hemodynamic
stability of a brain-dead organ donor. Despite a clear effect on
downregulating systemic proinflammatory cytokines, we did
not detect a significant improvement in surrogatemarkers for
organ function.
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